EGFR-RAD51 fusion
|
LUAD
|
EGFR-RAD51 fusion
|
LUAD
|
EGFR inhibitor Resistant: C3 – Early Trials
|
EGFR inhibitor Resistant: C3 – Early Trials
|
EGFR-RAD51 fusion
|
LUAD
|
EGFR-RAD51 fusion
|
LUAD
|
icotinib Sensitive: C4 – Case Studies
|
icotinib Sensitive: C4 – Case Studies
|
EGFR-RAD51 fusion
|
NSCLC
|
EGFR-RAD51 fusion
|
NSCLC
|
erlotinib Sensitive: C4 – Case Studies
|
erlotinib Sensitive: C4 – Case Studies
|
EGFR-RAD51 fusion
|
NSCLC
|
EGFR-RAD51 fusion
|
NSCLC
|
gefitinib Sensitive: C4 – Case Studies
|
gefitinib Sensitive: C4 – Case Studies
|
EGFR-RAD51 fusion
|
NSCLC
|
EGFR-RAD51 fusion
|
NSCLC
|
erlotinib + osimertinib Sensitive: C4 – Case Studies
|
erlotinib + osimertinib Sensitive: C4 – Case Studies
|